GlassScriptPhysician profile
Brian Marcus Clay
NPI 1295463784
$1,145.61
in general payments reported to CMS, 2019-2025
17 companies · $800 in 2025
The $800 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $191 · 2024: $154 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,145.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $197.03 | 2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $188.82 | 2025 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $136.90 | 2023-2024 | Xarelto |
| Pfizer INC. | $120.20 | 2023-2025 | |
| Glaxosmithkline, LLC. | $59.10 | 2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $58.50 | 2025 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.28 | 2025 | Jardiance |
| Boston Scientific Corporation | $49.89 | 2023-2025 | Opticross 35, Jetstream Sc, Eluvia |
| Lilly USA, LLC | $47.15 | 2025 | Mounjaro, Zepbound, Jardiance |
| Cardiva Medical, INC. | $45.15 | 2023-2024 | Cardiva Vascade 6/7f Vcs |
| Abbvie INC. | $39.32 | 2025 | |
| Lemaitre Vascular, INC. | $37.48 | 2023-2024 | Syntel Embolectomy Catheter (Spring Tip), Artegraft Vascular Graft |
| Dexcom, INC. | $32.97 | 2025 | Dexcom G6 Transmitter |
| Cordis US Corp. | $22.74 | 2023 | S.M.A.R.T. |
| Azurity Pharmaceuticals, INC. | $20.60 | 2025 | Azmiro |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.21 | 2025 | Caplyta |
| Corcept Therapeutics | $19.27 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Clay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.